Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Memory Aid by Intranasal Insulin in Diabetes (MemAID) (MemAID)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02415556
Recruitment Status : Recruiting
First Posted : April 14, 2015
Last Update Posted : June 21, 2019
Sponsor:
Collaborators:
Novo Nordisk A/S
Medtronic
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Information provided by (Responsible Party):
Vera Novak, Beth Israel Deaconess Medical Center

Tracking Information
First Submitted Date  ICMJE March 23, 2015
First Posted Date  ICMJE April 14, 2015
Last Update Posted Date June 21, 2019
Study Start Date  ICMJE July 2015
Estimated Primary Completion Date May 31, 2020   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: June 20, 2019)
  • Change from baseline Spatial Working Memory (SWM) between errors. [ Time Frame: Measured at weeks: 1 (twice, before and after intervention), 8, 16, 24 (last intervention), 32, 40, 48 (last follow-up) ]
    Spatial working memory - Difference between controls and diabetics at each time point
  • Change from baseline Paired Associates Learning (PAL) total errors (adjusted). [ Time Frame: Measured at weeks: 1 (twice, before and after intervention), 8, 16, 24 (last intervention), 32, 40, 48 (last follow-up) ]
    Visuospatial learning and memory - Difference between controls and diabetics at each time point
  • Change from baseline rapid visual processing (RVP) mean latency. [ Time Frame: Measured at weeks: 1 (twice, before and after intervention), 8, 16, 24 (last intervention), 32, 40, 48 (last follow-up) ]
    Rapid visual information processing - Difference between controls and diabetics at each time point
  • Change from baseline gait speed normal walk and dual task (both in cm/s). [ Time Frame: Measured at weeks: 1 (twice, before and after intervention), 8, 16, 24 (last intervention), 32, 40, 48 (last follow-up) ]
    Mobility in terms of gait speed - Difference between controls and diabetics at each time point
Original Primary Outcome Measures  ICMJE
 (submitted: April 13, 2015)
  • Change in Paired Associates Learning (PAL) total errors (adjusted) [ Time Frame: Measured at weeks: 1 (twice, before and after intervention), 8, 16, 24, 25 (last intervention), 32, 40, 48 (last follow-up) ]
    Visuospatial learning and memory - Difference between controls and diabetics at each time point
  • Change in Gait Speed [ Time Frame: Measured at weeks: 1 (twice, before and after intervention), 8, 16, 24, 25 (last intervention), 32, 40, 48 (last follow-up) ]
    Visuospatial learning and memory - The difference between the average of baseline and intervention 1 and each subsequent time point
  • Change in Fasting glucose [ Time Frame: Measured at screening and at weeks: 1-17, 19, 22, 24, 25 (last intervention), 32, 40, 48 (last follow-up) ]
    Safety outcome
Change History Complete list of historical versions of study NCT02415556 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures  ICMJE
 (submitted: June 20, 2019)
Change in fasting plasma and capillary glucose (mg/dL) [ Time Frame: Measured weekly during 24 weeks of intervention (week 1-24). ]
Long-term safety measure of intranasal insulin vs. placebo
Original Secondary Outcome Measures  ICMJE
 (submitted: April 13, 2015)
  • Magnetic Resonance Imaging (MRI) (Vasoreactivity) [ Time Frame: At weeks: 1 (twice, before and after intervention) and 24 ]
  • Hypoglycemic episodes [ Time Frame: At weeks: 1-25 (last intervention), 32, 40, 48 (last follow-up) ]
    Safety outcome
Current Other Pre-specified Outcome Measures
 (submitted: June 20, 2019)
Magnetic Resonance Imaging (MRI) (Vasoreactivity) - for 40 DM patients only [ Time Frame: At weeks: 1 (before intervention) and week 24 ( last intervention) ]
Vasoreactivity will be measured by pseudo-continuous arterial spin labeling (PCASL) MRI at 3 Tesla
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Memory Aid by Intranasal Insulin in Diabetes (MemAID)
Official Title  ICMJE Memory Advancement by Intranasal Insulin in Type 2 Diabetes
Brief Summary The main purpose of this study is to find the long-term effects of daily administration of 40 IU of intranasal insulin (INI) as compared to placebo (sterile saline) on cognition and memory in people with type 2 diabetes mellitus (DM), and non-diabetic controls over 24 weeks with a follow-up period for 24 weeks. Four groups will be tested: DM group treated with INI; DM group treated with placebo; control group treated with INI and the control group treated with placebo. The INI or placebo will be delivered into the nose. The investigators are interested to see whether INI can improve memory and cognition and blood flow in the brain in the type 2 DM group as compared to placebo and to the non-diabetic group over a long-term period.
Detailed Description

The investigators propose a randomized controlled trial determining the long-term effects of intranasal insulin (INI) on cognition and memory in type 2 diabetes (DM) and non-DM groups. The investigators hypothesize that: 1) INI-treated adults with DM have better memory and functioning of specific cognitive domains and faster walking during a dual task than those treated with placebo and the control group; 2) Glycemic and insulin resistance and genetic markers for Alzheimer's disease (Apolipoprotein E4 [ApoE4]) may serve as predictors of positive responses to INI therapy; 3) INI treatment neither adversely affects systemic glycemic levels or the cardiovascular system nor causes weight gain.

Aim 1: To determine whether INI-treated type 2 DM adults have a) better memory and functioning of specific cognitive domains and b) faster dual-task gait speed and better daily living functioning than the placebo-treated and non-DM groups. Four groups will be tested: 60 DM subjects treated with insulin; 60 DM subjects treated with placebo; 45 control subjects treated with INI and 45 control subjects treated with placebo. These 210 patients are expected to complete treatment and 168 are expected to complete study by the study completion anticipated date.

The investigators will conduct a randomized, double-blind, placebo-controlled study in 120 older adults with type 2 DM and 90 non-DM controls examining whether 40 IU INI once daily over a 24-week period improves:

  • Specific domains of visuospatial attention and memory, verbal learning (primary outcomes);
  • Gait speed during a dual task (which is an excellent predictor of overall health), daily living functionality, and depression as compared to the DM group receiving sterile saline and the non-DM groups. The non-DM groups will provide reference of INI effects in a clinical phenotype of cognitive decline and insulin resistance that occurs with normal aging.

Aim 2: To identify a phenotype and long-term trajectory predicting clinically relevant response to INI therapy based on glycemic control, insulin resistance, endothelial and genetic markers.

  1. The investigators will determine a phenotype predicting a clinically relevant response to INI therapy and identify time-dependent trajectories of INI effects on cognition in the DM group vs. the placebo and the non-DM groups. Clinical predictors will be based on associations between cognitive function and/or gait and demographic, glycemic control, insulin resistance, endothelial and genetic (ApoE4) measures.
  2. The investigators will evaluate the dose-escalating trajectory of cognition, gait speed, and functionality during the 24 weeks of therapy and 24 weeks post-treatment and their dependence on the above-mentioned factors, and determine the time point when maximum effect was reached. INI therapy response is defined as a clinically relevant improvement on cognitive tests or in gait speed (as a continuous variable) or as responders vs. non-responders as compared to placebo within DM and non-DM groups (as a categorical variable).
  3. MRI substudy: The investigators will explore the long-term INI effects on regional perfusion, vasodilatation, and resting functional connectivity in 40 DM subjects pre- and post- INI/placebo administration at the beginning and at the end of intervention and their relationships to cognitive outcomes. Regional perfusion and vasodilatation will be measured by pseudo-continuous arterial spin labeling (PCASL) MRI at 3 Tesla, and resting-state functional connectivity will be quantified from low-frequency (0.01-0.08 Hz) fluctuations (LFF) of the whole-brain blood-oxygen-level dependent (BOLD) functional Magnetic Resonance Imaging (fMRI).

Aim 3: To determine the long-term safety of INI vs. placebo with regard to glycemic control (fasting glucose, hemoglobin A1c [HbA1c], hypoglycemic episodes), vital signs, and body mass.

  1. The investigators will obtain measurements of fasting glucose, insulin, vital signs, and body mass at baseline, 2-months, 4-months, and 6-months follow-up and keep weekly logs monitoring glucose and adverse events.
  2. Safety substudy: In the first 20 DM patients treated with subcutaneous insulin, the investigators will conduct continuous glucose monitoring (CGM) OR 5 finger sticks/day (effective after 9/25/2017) for 1 week during baseline and during the first week of INI or placebo treatment to evaluate the INI effects on glycemic control, hypoglycemic episodes, and body weight.

This study may pave the way to potential treatment and/or cure of DM- and age-related cognitive decline.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:
120 T2DM adults and 90 non-DM controls (as of 9/25/2017)
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Condition  ICMJE Type 2 Diabetes Mellitus
Intervention  ICMJE
  • Drug: Regular Human Insulin
    Regular human insulin 40 IU daily over 24 weeks
    Other Name: Novolin R Novonordisk
  • Drug: Placebo
    Intranasal sterile saline 40 IU daily over 24 weeks
    Other Name: Sterile normal saline
Study Arms  ICMJE
  • Experimental: Type 2 Diabetes Mellitus - Insulin
    40 IU of regular human insulin once daily over 24 weeks
    Intervention: Drug: Regular Human Insulin
  • Placebo Comparator: Type 2 Diabetes Mellitus - Placebo
    Intranasal sterile saline once daily over 24 weeks
    Intervention: Drug: Placebo
  • Experimental: Control - Insulin
    40 IU of regular human insulin once daily over 24 weeks
    Intervention: Drug: Regular Human Insulin
  • Placebo Comparator: Control - Placebo
    Intranasal sterile saline once daily over 24 weeks
    Intervention: Drug: Placebo
Publications *

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: October 17, 2017)
360
Original Estimated Enrollment  ICMJE
 (submitted: April 13, 2015)
400
Estimated Study Completion Date  ICMJE June 2020
Estimated Primary Completion Date May 31, 2020   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Men and women aged 50-85 years old
  • Able to walk for 6 minutes
  • Diabetes type 2 (DM) group: diagnosis and treatment for type 2 DM with non-insulin oral or injectable agents
  • Non-DM group with similar age range as the DM group, non-diabetic fasting plasma glucose (<126 mg/dL) and hemoglobin A1c (HbA1c) (<6.5%)
  • Participants capable of providing informed consent

Exclusion Criteria:

  • Type 2 DM treated with insulin (since 9/25/2017)
  • Type 1 DM
  • Intolerance to insulin
  • History of severe hypoglycemia
  • Participants who have >1 asymptomatic and/or symptomatic episode of hypoglycemia (glucose < 54 mg/dL) during finger stick or plasma glucose (cut off value since 6/11/2018)
  • Acute medical condition that required either hospitalization or surgery within the past 6 months (e.g., severe hypoglycemia, malignancies, myocardial infarction,stroke)
  • Liver or renal failure or transplant
  • Dementia (Mini Mental State Examination [MMSE] scores ≤20)
  • Current recreational drug or alcohol abuse
  • Serious systemic disease that would interfere with conduction of clinical trial (mild forms of neurological conditions e.g. Parkinson's Disease, autonomic neuropathy etc. would be allowed)
  • Magnetic Resonance Imaging (MRI) substudy in 40 DM patients only: claustrophobia and implants incompatible with 3-Tesla MRI
  • Safety substudy in 20 IDDM patients only: Insulin-treated type 2 diabetics with a C-peptide of <0.8 ng/mLd and fasting blood glucose >150 mg/dL will be excluded even without history of hypoglycemia during finger stick measurements.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 50 Years to 85 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE
Contact: Laura Aponte-Becerra 617-632-8883 laponte@bidmc.harvard.edu
Contact: Jorge Trevino 617-632-8859 jtrevin1@bidmc.harvard.edu
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT02415556
Other Study ID Numbers  ICMJE 2015P000064
1R01DK103902-01A1 ( U.S. NIH Grant/Contract )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE
Plan to Share IPD: Yes
Plan Description: BWH's site data will be shared with BIDMC site upon BWH's site recruitment initiation
Responsible Party Vera Novak, Beth Israel Deaconess Medical Center
Study Sponsor  ICMJE Beth Israel Deaconess Medical Center
Collaborators  ICMJE
  • Novo Nordisk A/S
  • Medtronic
  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Investigators  ICMJE
Principal Investigator: Vera Novak, PhD Beth Israel Deaconess Medical Center
Principal Investigator: Peter Novak, MD PhD Brigham and Women's Hospital
PRS Account Beth Israel Deaconess Medical Center
Verification Date June 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP